Category: Clinical Case & Protocol Review

Subject: Longitudinal Analysis of Targeted Cerebrovascular Neural Regenerative Therapy

Core Metrics: EDSS Reduction from 6.0 to 2.5; Verified 5-Year Radiographic Stability; Discontinuation of Traditional Disease-Modifying Therapy (DMT).

Executive Case Summary

This clinical review evaluates the 6-year longitudinal trajectory of Cindy Bodily, a patient diagnosed with Relapsing-Remitting Multiple Sclerosis (RRMS) in 1994. In January 2020, presenting with a baseline Expanded Disability Status Scale (EDSS) score of 6.0, the patient underwent an experimental, multi-phased cerebrovascular neural regenerative protocol developed by Somata Genesis.

Post-therapeutic metrics document a rapid functional shift, with her EDSS score dropping to 3.0 within 30 days, further stabilizing at 2.5 by Year 1. This state of minimal disability has persisted through 2026. A 5-year longitudinal MRI comparison (2020–2025) objectively confirms the arrest of disease progression, with zero new lesions detected. Concurrently, the patient safely discontinued all traditional neurosuppressive medications and DMTs immediately before the 2020 intervention and remains entirely medicine-free at age 68.

I. Structural Mimicry & Confounding Pathologies

Evaluating high-baseline EDSS patients requires differentiating between active immune-mediated demyelination and structural abnormalities that mimic upper motor neuron damage. The patient’s extensive surgical history presents significant mechanical confounders:

• 2005 Intracranial Meningioma Excision: Craniotomy for a primary central nervous system tumor leaves localized parenchymal scarring and permanently alters local cerebrospinal fluid (CSF) dynamics, which can exacerbate or confound long-term sensory-motor tracks.
• 2013 Cervical Vertebral Fusion: Misaligned cervical vertebrae frequently induce cervical spondylotic myelopathy (CSM). CSM mechanically compresses the spinal cord, causing spasticity, hyperreflexia, and gait ataxia—deficits that perfectly mimic MS plaques on a standard neurological examination.
• Comorbid Herniated Intervertebral Discs: In patients with an EDSS > 5.0, progressive foraminal narrowing and radiculopathy often compound or mimic peripheral neuropathy and limb spasticity.

II. The Mechanistic Rationale of the Somata Genesis Protocol

Unlike uncharacterized, cross-border stem cell clinics that rely on systemic, blind mesenchymal stem cell (MSC) infusions, the Somata Genesis protocol employs a highly selective, pathophysiologically targeted strategy explicitly tailored to the vascular and structural anatomy of MS.

1. Cerebrovascular Preconditioning & Outflow Dynamics

A core tenet of the protocol addresses a frequently overlooked aspect of MS pathology: restricted intracranial venous outflow. Obstructions such as cerebral venous sinus thrombosis, internal jugular vein (IJV) stenosis, Eagle’s syndrome, or lymphovenous blocks severely impede the drainage of deoxygenated blood and CSF.

[Venous Outflow Obstruction] 

│

▼

[Elevated Intracranial Pressure] ──► [Pituitary Compression / Empty Sella Syndrome]

│

▼

[Ischemic Hypoxia & Hypoperfusion] ──► [Juxtacortical “Leisons” / Structural Damage]

This mechanical backlog creates chronic tissue hypoxia and localized ischemia, which neurologists frequently visualize on MRIs as fresh juxtacortical lesions. Furthermore, the resulting elevated intracranial pressure can cause excessive pituitary compression, manifesting radiographically as empty sella syndrome—a phenomenon documented with high frequency in MS cohorts.

To resolve this, the protocol initiates a cerebrovascular preconditioning stage. By targeting endothelial tissue regeneration and deploying precise growth factors, the procedure aims to resolve microthromboses within the cerebral venous sinuses, re-establishing normal venous hemodynamics and restoring the oxygenated blood flow necessary to support cellular repair.

2. Selective Supratentorial Delivery

In RRMS, the supratentorial region, the corpus callosum, and the surrounding periventricular structures bear the primary burden of demyelinating plaques, which are clearly visible on sagittal MRI.

To maximize bioavailability and bypass the limitations of systemic circulation, the protocol utilizes highly selective catheterization. Formulated cellular products and neurotrophic factors are delivered directly to the supratentorial brain and spine via the sigmoid sinuses. This approach provides an efficient, anatomically direct pathway to the primary sites of neuro-inflammation and demyelination.

3. Targeted Neurogenesis and Neuropathy Resolution

The protocol achieves its regenerative endpoints through a multi-tiered cellular deployment:

• Immunomodulatory & Endothelial Target: The protocol is designed to address specific B-cell activity and its destructive autoimmune impacts on endothelial, epithelial, and oligodendrocyte targets.
• Neuroplasticity Layer: A precisely formulated, characterized, and dosed mix of neural progenitors and neurotrophic factors is introduced to replicate the natural neurogenesis and neuroplasticity typically native to a young brain.
• Radiculopathy Decompression: Because the patient possessed a history of herniated discs, a third localized procedure was rendered to directly treat foraminal narrowing and radiculopathy, clearing the peripheral mechanical blockages that were compounding her lower-limb spasticity.

III. Clinical Outcome and Translational Interpretation

CINDY’S 30-YEAR LONGITUDINAL TRAJECTORY:

[1994] Diagnosed with RRMS

│

▼ 

[2005] Meningioma Brain Surgery

│

▼ 

[2013] Cervical Vertebral Fusion

│

▼ 

[2020] Baseline EDSS 6.0 ──► [Somata Genesis Protocol Interventions]

│

▼

[Post-Therapy 30 Days] ──► EDSS Drops to 3.0

│

▼ 

[Post-Therapy 1 Year] ──► EDSS Stabilizes at 2.5 (Remains stable through 2026)

│

▼ 

[2020–2025 MRI Track] ──► 5-Year Comparison Confirms Zero Disease Progression

The Immunosenescence Interface

The patient sustained a 6-year remission, and her ability to remain off DMTs up to age 68 must be analyzed alongside the natural aging process of the immune system. As patients enter their sixth and seventh decades, immunosenescence naturally downregulates the acute, peripheral B-cell- and T-cell-driven inflammatory responses responsible for classic RRMS relapses.

However, while immunosenescence can naturally slow new gadolinium-enhancing lesion activity (which correlates with her stable 5-year MRI), it does not typically reverse a sustained EDSS of 6.0 to 2.5. The rapid, profound improvement in her ambulatory status within 30 days indicates that addressing the mechanical radiculopathy, resolving venous sinus outflow obstructions, and delivering targeted neural progenitors to the supratentorial region successfully resolved a massive burden of reversible neurological deficit (penumbra) rather than completely irreversible axonal transection.

IV. Patient Testimonial (Verified 2022)

For context regarding the functional impact of this protocol, the patient’s direct perspective provides valuable insight into her post-therapeutic quality of life:

“I am a 64-year-old female who has been battling multiple sclerosis for over 25 years. In 2019, I learned about a stem cell treatment that might help me heal from some of the damaging effects of MS. I traveled to India in January of 2020, where I received stem cell treatment from Surjo Banerjee and his team at Somata Genesis.

What a blessing this treatment has been. I no longer take any of the MS drugs, and most importantly, I can walk normally again. This treatment has healed me from other MS damage as well. I feel like I am now free to live a normal life. I would highly recommend this treatment to anyone who has suffered from the debilitating effects of multiple sclerosis.” — Cindy Bodily, 2022

Conclusion

The Somata Genesis protocol represents a highly specialized deviation from standard autologous hematopoietic stem cell transplantation (aHSCT) and unregulated peripheral stem cell therapies. By matching the clinical rationale to the precise cerebrovascular, venous, and structural microenvironments of MS—specifically, by correcting venous sinus obstructions and delivering localized supratentorial neural progenitors—the protocol successfully unlocked an unexpected degree of neurological recovery.

For multi-comorbid patients presenting with high EDSS scores, this case underscores a vital clinical lesson: addressing secondary mechanical, ischemic, and vascular blockages is an essential prerequisite for any successful neuro-regenerative strategy.

References

Chung, C. P., Beggs, C., Wang, P. N., Bergsland, N., Shepherd, S., Cheng, C. Y., Ramasamy, D. P., Dwyer, M. G., Hu, H. H., & Zivadinov, R. (2014). Jugular venous reflux and white matter abnormalities in Alzheimer’s disease: a pilot study. Journal of Alzheimer’s disease : JAD, 39(3), 601–609. https://doi.org/10.3233/JAD-131112

Zivadinov, R., Marr, K., Cutter, G., Ramanathan, M., Benedict, R. H., Kennedy, C., Elfadil, M., Yeh, A. E., Reuther, J., Brooks, C., Hunt, K., Andrews, M., Carl, E., Dwyer, M. G., Hojnacki, D., & Weinstock-Guttman, B. (2011). Prevalence, sensitivity, and specificity of chronic cerebrospinal venous insufficiency in MS. Neurology, 77(2), 138–144. https://doi.org/10.1212/WNL.0b013e318212a901

Lucchinetti, C. F., Popescu, B. F., Bunyan, R. F., Moll, N. M., Roemer, S. F., Lassmann, H., Brück, W., Parisi, J. E., Scheithauer, B. W., Giannini, C., Weigand, S. D., Mandrekar, J., & Ransohoff, R. M. (2011). Inflammatory cortical demyelination in early multiple sclerosis. The New England journal of medicine, 365(23), 2188–2197. https://doi.org/10.1056/NEJMoa1100648

Yang, L., Liu, S. C., Liu, Y. Y., Zhu, F. Q., Xiong, M. J., Hu, D. X., & Zhang, W. J. (2024). Therapeutic role of neural stem cells in neurological diseases. Frontiers in bioengineering and biotechnology, 12, 1329712. 

Harris, V. K., Bishop, D., Wollowitz, J., Carling, G., Carlson, A. L., Daviaud, N., & Sadiq, S. A. (2023). Mesenchymal Stem Cell-Derived Neural Progenitors Attenuate Proinflammatory Microglial Activation Via Paracrine Mechanisms. Regenerative Medicine, 18(3), 259–273. https://doi.org/10.2217/rme-2023-0005

Kappos, L., Wolinsky, J. S., Giovannoni, G., Arnold, D. L., Wang, Q., Bernasconi, C., Model, F., Koendgen, H., Manfrini, M., Belachew, S., & Hauser, S. L. (2020). Contribution of Relapse-Independent Progression vs Relapse-Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Analysis of 2 Randomized Clinical Trials. JAMA neurology, 77(9), 1132–1140. https://doi.org/10.1001/jamaneurol.2020.1568

#MultipleSclerosis #NeuroRegeneration #TranslationalMedicine #Cerebrovascular#Neuroplasticity #Neuroscience #MSFree #NeurologyReview #ClinicalResearch#EmptySellaSyndrome #VenousOutflow #Biologics #StemCellProtocol #MedicalCaseStudy#MSWarrior